Regorafenib-A feasible option as third-line therapy of recurrent glioblastoma?
Alice Dauth (Mainz), Harald Krenzlin (Mainz), Felipa Lange (Mainz), Florian Ringel (Mainz), Naureen Keric (Mainz)